在乳腺癌进展和治疗方法中 EGFR 家族的体内建模。
In vivo modeling of the EGFR family in breast cancer progression and therapeutic approaches.
机构信息
Rosalind and Morris Goodman Cancer Research Center, McGill University, Montreal, QC, Canada; Department of Biochemistry, McGill University, Montreal, QC, Canada.
Rosalind and Morris Goodman Cancer Research Center, McGill University, Montreal, QC, Canada; Department of Biochemistry, McGill University, Montreal, QC, Canada; Faculty of Medicine, McGill University, Montreal, QC, Canada.
出版信息
Adv Cancer Res. 2020;147:189-228. doi: 10.1016/bs.acr.2020.04.004. Epub 2020 Jun 16.
Modeling breast cancer through the generation of genetically engineered mouse models (GEMMs) has become the gold standard in the study of human breast cancer. Notably, the in vivo modeling of the epidermal growth factor receptor (EGFR) family has been key to the development of therapeutics and has helped better understand the signaling pathways involved in cancer initiation, progression and metastasis. The HER2/ErbB2 receptor is a member of the EGFR family and 20% of breast cancers are found to belong in the HER2-positive histological subtype. Historical and more recent advances in the field have shaped our understanding of HER2-positive breast cancer signaling and therapeutic approaches.
通过生成基因工程小鼠模型（GEMMs）来模拟乳腺癌已成为研究人类乳腺癌的金标准。值得注意的是，表皮生长因子受体（EGFR）家族的体内建模是开发治疗方法的关键，并且有助于更好地了解参与癌症发生、进展和转移的信号通路。HER2/ErbB2 受体是 EGFR 家族的一员，20%的乳腺癌被发现属于 HER2 阳性组织学亚型。该领域的历史和最新进展塑造了我们对 HER2 阳性乳腺癌信号和治疗方法的理解。
Zotero 插件